![Flow Cytometry - EpCAM antibody [B29.1 (VU-ID9)] (FITC) (ab8666) image](#ab8666_11.jpg)
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - EpCAM antibody [B29.1 (VU-ID9)] (FITC) (ab8666) image](#EpCAM-Primary-antibodies-ab8666-1.jpg)
![Immunocytochemistry/ Immunofluorescence-EpCAM antibody [B29.1 (VU-ID9)] (FITC)(ab8666) image](#EpCAM-Primary-antibodies-ab8666-2.jpg)
Loading...
You have changed your country from
to
. Please be aware that this will change the currency in the purchasing process.
Products:Tags & Cell Markers >> Cell Type Markers >> Tumor Associated
Overview
Product name
Anti-EpCAM antibody [B29.1 (VU-ID9)] (FITC)
See all EpCAM products (24) ...
Description
Mouse monoclonal [B29.1 (VU-ID9)] to EpCAM (FITC)
Conjugation
FITC
Conjugation notes
Fluorescein (FITC) conjugated at a ratio of 6 moles of Fluorescein to 1 mole of antibody. Maximum excitation of FITC occurs at wavelength 492 nm and maximum emission occurs at wavelength 520 nm.
Specificity
This antibody reacts with a 40 kD cell surface glycoprotein called ESA.
Tested applications
ICC, IHC-P, WB, IP, ICC/IFmore details
Cross reactivity
Reacts with
Human
Immunogen
Small cell lung carcinoma cell line.
Positive control
Breast, colon carcinoma and tonsil
General notes
Dilute according to the particular application being used.
In general, 0.05M borate pH 8.0 containing 0.15M sodium chloride, 0.02% sodium azide, is a good dilutent to use with most antibodies.
Avoid diluting the entire contents of the vial at once since the diluted solution may have reduced stability.
Properties
Form
Liquid
Storage instructions
Store at +4°C. Do not freeze.
Storage buffer
pH: 7.40
Preservative: 0.1% Sodium azide
Constituent: 0.01% PBS
Concentration
Concentration information loading...
Purity
Protein G purified
Clonality
Monoclonal
Clone number
B29.1 (VU-ID9)
Isotype
IgG1
Light chain type
kappa
Research areas
Tags & Cell Markers >> Cell Type Markers >> Epi / Endo-thelial
Tags & Cell Markers >> Cell Type Markers >> Tumor Associated
-
Flow Cytometry - EpCAM antibody [B29.1 (VU-ID9)] (FITC) (ab8666)
![Flow Cytometry - EpCAM antibody [B29.1 (VU-ID9)] (FITC) (ab8666) image](/ps/datasheet/Images/8/ab8666/ab8666_11.jpg)
(enlarge)
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - EpCAM antibody [B29.1 (VU-ID9)] (FITC) (ab8666)
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - EpCAM antibody [B29.1 (VU-ID9)] (FITC) (ab8666) image](/ps/datasheet/images/8/ab8666/EpCAM-Primary-antibodies-ab8666-1.jpg)
(enlarge)
-
Immunocytochemistry/ Immunofluorescence-EpCAM antibody [B29.1 (VU-ID9)] (FITC)(ab8666)
![Immunocytochemistry/ Immunofluorescence-EpCAM antibody [B29.1 (VU-ID9)] (FITC)(ab8666) image](/ps/datasheet/images/8/ab8666/EpCAM-Primary-antibodies-ab8666-2.jpg)
(enlarge)
Applications
Show applications key
Our Abpromise guarantee covers the use of ab8666 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
ICC: Use a concentration of 5 - 10 µg/ml.(PubMed: 17417652)
IHC-P: Use a concentration of 5 - 10 µg/ml.(PubMed: 20421921)
WB: Use a concentration of 1 - 5 µg/ml.(
This product was not quality controlled in Flow Cytometry applications. However, it may be applicable for Flow Cytometry at a concentration of 1-2 µg in 0.1 ml containing 10^6 cells.)IP: Use at an assay dependent concentration.
ICC/IF: Use a concentration of 5 - 10 µg/ml.(See Abreview.)
Target
Function
May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E.
Tissue specificity
Highly and selectively expressed by undifferentiated rather than differentiated embryonic stem cells (ESC). Levels rapidly diminish as soon as ESC's differentiate (at protein levels). Expressed in almost all epithelial cell membranes but not on mesodermal or neural cell membranes. Found on the surface of adenocarcinoma.
Involvement in disease
Defects in EPCAM are the cause of diarrhea type 5 (DIAR5) [MIM:613217]. It is an intractable diarrhea of infancy characterized by villous atrophy and absence of inflammation, with intestinal epithelial cell dysplasia manifesting as focal epithelial tufts in the duodenum and jejunum.
Defects in EPCAM are a cause of hereditary non-polyposis colorectal cancer type 8 (HNPCC8) [MIM:613244]. HNPCC is a disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, HNPCC is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. Note=HNPCC8 results from heterozygous deletion of 3-prime exons of EPCAM and intergenic regions directly upstream of MSH2, resulting in transcriptional read-through and epigenetic silencing of MSH2 in tissues expressing EPCAM.
Sequence similarities
Belongs to the EPCAM family.
Contains 1 thyroglobulin type-1 domain.
Post-translational
modifications
Hyperglycosylated in carcinoma tissue as compared with autologous normal epithelia. Glycosylation at Asn-198 is crucial for protein stability.
Cellular localization
Lateral cell membrane. Cell junction > tight junction. Co-localizes with CLDN7 at the lateral cell membrane and tight junction.
Target information above from: UniProt accessionP16422
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).
Alternative names
- 17 1A antibody
- 323/A3 antibody
- Adenocarcinoma associated antigen antibody
see all
Database links
- Entrez Gene: 4072 Human
- Omim: 185535 Human
- SwissProt: P16422 Human
- Unigene: 542050 Human
Anti-EpCAM antibody [B29.1 (VU-ID9)] (FITC) images:
Flow Cytometry - EpCAM antibody [B29.1 (VU-ID9)] (FITC) (ab8666)
Histogram plot of prostate tumour cells DU145 (green) over isotype control (red) stained with EpCam following resection.
This picture was kindly supplied as part of the review submitted by Phil Kearney.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - EpCAM antibody [B29.1 (VU-ID9)] (FITC) (ab8666)
ab8666 staining EpCAM in murine xenograft tumour derived from human DCIS cells by Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections). The sections were deparaffinized in xylene, and rehydrated in graded alcohols. Sections were then incubated at room temperature with ab8666 at 5 µg/ml. Slides were rinsed in borate buffer pH 8 and counterstained. EpCAM-FITC pseudo-colored green, 488 nm and DAPI psuedo-colored blue, 408 nm.
Image from Espina V et al, PLoS One. 2010 Apr 20;5(4):e10240, Fig 1.
Immunocytochemistry/ Immunofluorescence-EpCAM antibody [B29.1 (VU-ID9)] (FITC)(ab8666)
ICC/IF image of ab8666 stained HepG2 cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab8666, 5µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-mouse IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
References for Anti-EpCAM antibody [B29.1 (VU-ID9)] (FITC) (ab8666)
This product has been referenced in:
- Kondo Set al. Epstein-barr virus latent membrane protein 1 induces cancer stem/progenitor-like cells in nasopharyngeal epithelial cell lines. J Virol 85:11255-64 (2011).Read more (PubMed: 21849440) »
- Espina Vet al. Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival. PLoS One 5:e10240 (2010). IHC-P; Human.Read more (PubMed: 20421921) »
See all 6 publications for this product
Publishing research using ab8666? Please let us know so that we can cite the reference in this datasheet
![EpCAM antibody [B29.1 (VU-ID9)] (FITC) for FACS in Human (8666)](/ps/Reviews/Images/ab6362_23651.jpg)
![EpCAM antibody [B29.1 (VU-ID9)] (FITC) for ICC in Human (8666)](/ps/Reviews/Images/ab5928_21203.jpg)
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"